U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,184.82
    +37.90 (+1.77%)
     
  • Crude Oil

    66.27
    +2.44 (+3.82%)
     
  • Gold

    1,697.30
    -3.40 (-0.20%)
     
  • Silver

    25.23
    -0.23 (-0.91%)
     
  • EUR/USD

    1.1920
    -0.0059 (-0.49%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3844
    -0.0049 (-0.36%)
     
  • USD/JPY

    108.3590
    +0.3830 (+0.35%)
     
  • BTC-USD

    49,270.66
    +1,259.77 (+2.62%)
     
  • CMC Crypto 200

    983.97
    +40.79 (+4.33%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Veru Files US Application For TADFIN Combo For Prostate Enlargement

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Veru Inc (NASDAQ: VERU) has submitted a 505(b)(2) New Drug Application with the FDA for TADFIN (tadalafil 5mg and finasteride 5mg) capsules, daily oral dosing combination formulation, for the treatment of benign prostatic hyperplasia (BPH), also called prostate gland enlargement.

  • The agency's goal date is expected in December 2021.

  • TADFIN revenues will be part of Veru's sexual health commercial business.

  • Eli Lily and Co's (NYSE: LLY) CIALIS (tadalafil) is currently approved for the treatment of BPH and erectile dysfunction, and Merck & Co Inc's (NYSE: MRK) MPROSCAR (finasteride) is approved for male pattern hair loss (androgenic alopecia).

  • The company's stock rallied after it announced positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome from SARS-CoV-2.

  • Price Action: VERU is down 6.9% at $15.3 on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.